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Abstract 
Bronchopulmonary dysplasia (BPD), defined as the need for oxygen at 28 days of 
life, develops in preterm infants as a result of ventilatory strategies used to manage acute 
respiratory illness. The incidence rate of BPD is increasing as more and more extremely 
preterm infants survive acute respiratory illness. Inadequate growth is the most common 
morbidity affecting these infants, with attained weights well below the 10th percentile. 
One area in need of further research is the examination of the ability of the preterm 
infants with BPD to digest provided nutrients. The only study to date found that these 
infants have decreased pancreatic activity and increased fecal losses of nutrients, 
excreting 21.4% of fat intake and 13.5% of protein intake. This is an important finding 
given that the standard of care is to increase nutrients to promote growth. The purpose of 
this exploratory study was to examine pancreatic enzyme activity in preterm infants with 
BPD. Data were collected on preterm infants on full enteral nutrition at approximately 33 
weeks post-conceptional age. Fecal elastase-1 levels (μg/gm of stool) were measured and 
compared to the expected normal value of 200 μg/gm of stool. Enzyme-linked 
immunosorbent assay (ELISA) was used to determine fecal elastase-1 levels. In our 
laboratory, the coefficient of variation for assays is less than 10%. To date, there has been 
very limited examination of the ability of preterm infants with BPD to digest the nutrients 
provided. The anticipated findings from this proposed project should provide a better 
understanding of digestion and provide the foundation for further study of gastrointestinal 
function in preterm infants with BPD.   
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Chapter 1 
Introduction 
Premature birth is a major problem affecting the infant population. In 2006, there 
were 542,893 preterm births in the United States, representing 12.8% of all live births 
(National Center for Health Statistics, final natality data). Majority of these preterm 
infants develop Respiratory Distress Syndrome (RDS), which is the most frequently 
observed severe acute illness in this population (Martin et al., 2002). Within this class, 
Bronchopulmonary Dysplasia is the most common form of chronic infant lung disease 
and the most common cause of morbidity and death among these preterm infants. Many 
advances in the treatment of preterm infants with BPD have been discovered and 
implemented and thus, the survival rates of these infants have increased. Several 
examples of new these new treatments include an increase in the usage of 
glucocorticosteroids, exogenously supplied surfactant, and technologically advanced 
ventilator strategies (Coalson, 2003). Despite the increased survival rate of the preterm 
infants with BPD, the incidence rate of BPD still remains high. Thus, the search for new 
technologies to decrease the occurrence rate of BPD and to improve the outcomes 
continues to be a pressing issue.  
 Growth is one of the most essential therapies for preterm infants with BPD. This 
is because lung growth and development are closely related to the rate of somatic growth. 
However, this is problematic because inadequate growth and nutrition intake is one of the 
common morbidities affecting the preterm infants with BPD (Karn & Steward, 2005). 
While many health care providers recommend increasing the macronutrient caloric intake 
of these infants in order for them to grow, research suggests that this may not be the best 
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solution (Carroll, Slobozian, & Steward, 2005). The reason for this is that very little is 
known about the digestive and absorptive ability of premature infants with BPD 
(Campeotto et al., 2007). Thus, this could indicate that preterm infants with BPD are not 
able to properly absorb or digest macronutrients and that calories are being lost 
throughout the digestive process. Thus, the preterm infants with BPD are unable to 
maintain the same growth rate as a stable preterm infant of the same age without BPD 
(Karn & Steward, 2005). 
 Since more research is needed in this area, fecal pancreatic enzyme elastase-1 
(FE-1) levels will be examined across time in preterm infants with BPD. FE-1 was the 
chosen pancreatic enzyme because of its ability to remain stable throughout the digestive 
and absorptive processes (Kori, Maayan-Metzger, Shamir, Sirota, & Dinari, 2003). Thus, 
the FE-1 concentration level determined from the collected stool samples will be used to 
help determine the exocrine pancreatic function and capacity of the preterm infants with 
BPD. 
 Within this study, several aspects of the preterm infant’s nutrition, weight gain, 
and FE-1 levels will be examined. The FE-1 levels of the preterm infants with BPD will 
be examined and compared to the normal FE-1 level, that is considered to be equal to or 
greater than 200 µg/gm of stool. The hypothesis is that preterm infants with BPD will 
have inadequate FE-1 levels and thus, will fall below the normal range of 200 µg/gm of 
stool. By conducting this research, a better understanding of the digestive and absorptive 
abilities of these preterm infants with BPD will be able to be determined.  
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Chapter 2 
Review of Literature 
A. BPD  
With the improved survival rate of smaller, preterm infants that has been seen in 
recent years, BPD has become a common morbidity among this population. It is 
estimated that 77% of extremely low birth weight infants develop BPD (Ehrenkranz et 
al., 2005). In the United States alone, the annual cost to care for preterm infants with 
BPD is estimated to be around $2.4 billion (National Institute of Health, 1998). BPD is 
defined as the requirement of supplemental oxygen and/or mechanical ventilation support 
at 28 days of life (Ehrenkranz et al., 2005). This support results in treatment-induced 
injury, which causes an inflammatory cascade and results in hypoalveolarization 
(Coalson, 2003). BPD is a disruption in the normal lung development with the main 
pathophysiological changes being alveolar simplification and impaired angiogenesis of 
the lungs (Thebaud & Abman, 2007). Children with a history of BPD also have an 
increased risk of developing developmental disorders, lower pulmonary functioning, 
growth retardation, and academic difficulties in school (Anderson & Doyle, 2006; Eber, 
2001)In addition, this chronic disease can have a major impact on the daily lives of the 
families caring for these preterm infants with BPD (Kobaly et al., 2007). While more data 
is being collected and new strategies are being implemented, the incidence of BPD 
continues to remain high (Wadhawan et al., 2007).  
B. BPD and Growth 
 Failure to grow in infants with BPD is a major issue. Growth accounts for the 
largest amount of energy expended in infants (Pridham et al., 2007). Inadequate 
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nutritional intake, poor intestinal absorption, and increased energy expenditure are all 
factors that can contribute to this poor growth rate (Boehm et al., 1996). The goal weight 
gain for preterm infants is to be at approximately the same rate as the expected 
intrauterine rate of growth of a fetus. This rate is 15 g/kg/day (American Academy of 
Pediatrics, 1998). However, if the preterm infant is not able to maintain a growth rate of 
15 g/kg/day or higher, it is projected that the weight gain of the infant will be five to six 
weeks behind that of the growing fetus (Heird, 2001). Furthermore, even if the goal 
growth rate is able to be met, it is extremely hard to maintain this growth rate because of 
the preterm infant’s physiologic immaturity.  
 Furthermore, while a 10% weight loss following birth is expected in infants, the 
low weight preterm infants are expected to lose between approximately 15%-20% of their 
birthweight. By 36 weeks postconceptional age, 99% of these infants have fallen below 
the 10
th
 percentile for growth.  (Carroll et al., 2005). This is important because it shows 
that the preterm infants with BPD develop a significant growth deficient that can be hard 
to overcome when taking into account all of the other contributing factors (Ehrenkranz et 
al., 1999).  
 In the longitudinal study performed by Boehm et al. (1996), several factor were 
examined to determine the degree to which each of these factors affected the growth rate 
in preterm infants with BPD. These factors included mean duodenal lipase and trypsin 
activity levels, mean total bile acid concentrations, fecal fat excretion, and nitrogen 
concentration levels in preterm infants. They examined these factors in preterm infants 
with BPD, preterm infants without BPD, and term infants, who were used as the control 
group. The lipase, trypsin, and bile acid concentration levels were obtained by inserting a 
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transpyloric tube into the duodenum and preprandially aspirating digestive fluid (Boehm 
et al.,1996). Stool samples were used to determine total nitrogen and total fat levels. The 
results of the Boehm study showed that preterm infants with BPD had a decrease in 
pancreatic enzyme sufficiency and limited fat absorption. They also showed that both of 
these factors may result in inadequate weight gain and an insufficient growth rate in the 
preterm infants.  
 The small amount of research that has been conducted in this area shows that the 
preterm infants with BPD have an increased energy expenditure that may contribute to 
their inability to gain weight at the same rate as the expected intrauterine growth rate. In 
order for growth to occur, the caloric intake must exceed the amount of energy expended 
(Carroll et al., 2005). Energy expenditure can be defined as the physiologic processes that 
fuel growth, development and other life processes. (Pridham et al., 2007).  In the 
longitudinal study performed by Pridham et al. (2007), several biobehavioral variables 
that affect energy expenditure levels in preterm infants were examined. The researchers 
examined the infants activity level, caloric intake, biological maturity level, history of 
lung disease,  and daily weight gain to determine the effects these factors had on the 
infants energy expenditure levels. To determine the amount of energy spent with each 
activity, a metabolic gas monitor indirect calorimeter was used. The results showed that a 
lung disease history, mean activity levels, and time were all important factors in 
determining energy expenditure in these preterm infants (Pridham et al, 2007). Thus, the 
more energy these preterm infants expend, the less they have available for growth. By 
determining the factors that have the largest impact on energy expenditure levels, 
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measures can be taken to minimize this energy loss, allowing more energy to be directed 
toward the preterm infant’s growth processes.  
C. Nutrition 
Nutrition is one of the factors that plays a major role in growth and development. 
A significant portion of poor growth rates in preterm infants with BPD can be attributed 
to inadequate nutrition (Ziegler, Thureen, & Carlson, 2002). Thus, nutritional support has 
become an essential component in the provision of care for these infants (Embeleton, 
Pang, & Cooke, 2001). Research has shown that in the first few weeks post-birth, the 
preterm infants suffering from BPD receive significantly fewer calories than the stable 
preterm infants. (deRegnier, Guilbert, Mills,  & Georgieff, 1996). Furthermore, the 
preterm infants received below the daily caloric and protein recommendations, which 
were 120 kcal/kg/day and 3 g/kg/day respectively (Ziegler et al., 2002). This resulted in a 
significant energy and protein deficiency and a cumulative energy deficiency of 598 
kcal/kg (Karn & Steward, 2005). Thus, there is a limited amount of protein and fat 
available for the deposition of new body tissue. Because of this, the ability of the infant to 
grow is limited. (Carroll et al., 2005).   
 Another problem that is being faced by healthcare providers initiating nutritional 
support in preterm infants with BPD is the lack of universal nutritional guidelines. This 
results in nutritional practices that vary greatly in regards to the initial introduction of 
parenteral nutrition, the amount of macronutrients initiated, and the pace at which to 
advance these macronutrients (Carroll et al., 2005). One recommendation by Ziegler 
(2002) is to introduce enteral nutrition earlier in order to stimulate the maturation process 
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of the gastrointestinal tract. By doing this the infant will have a quicker advancement to 
full enteral feedings.  
 It is clear that inadequate nutrition related to growth deficiency is a large problem 
affecting preterm infants with BPD. While it is not clear how undernourished these 
infants actually are, it is hypothesized that the preterm infants with BPD require higher 
intake levels of protein, fat, and calories than stable preterm infants in order to establish 
the recommended growth rates (Karn & Steward, 2005).  
D. BPD and Nutrient Digestion and Absorption 
Providing adequate nutrition to preterm infants with BPD not only depends on the 
amount of calories, protein and fat provided, but also on the infants’ physiologic ability to 
digest and absorb these nutrients. BPD is associated with a chronic inflammatory 
response and metabolic/respiratory acidotic state (Coalson, 2003). This makes it difficult 
for the body, including the gastrointestinal tract, to function properly. Since minimal 
research has been conducted in this area, the functionality of the GI system in preterm 
infants with BPD is an area in which little is known.  
There is some evidence, however, that indicates that preterm infants with 
respiratory disease have decreased pancreatic activity levels. The most accurate way to 
determine pancreatic enzyme activity involves using a transpyloric tube to aspirate the 
enzymes in the duodenum. However, this method is highly invasive, costly and can be 
extremely stressful to the already unstable infants. Because of this, FE-1is used as a 
marker to determine the exocrine pancreatic function. FE-1 is the most common 
pancreatic enzyme used to measure the pancreatic secretory capacity and exocrine 
function in preterm infants with BPD (Kori et al., 2003). FE-1 is considered to be a 
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highly specific and sensitive marker for pancreatic exocrine function and is able to 
remain stable throughout the intestinal transit (Campeotto et al., 2002; Kori et al., 2003). 
In addition, the FE-1 concentration is independent of any of the other exogenous 
pancreatic enzymes within the endocrine system (Nissler, Von Katte, Huebner, & 
Henker, 2001). Because of all of these factors, FE1 is thought to be the most efficient 
pancreatic enzyme in diagnosing pancreatic insufficiency (Campeotto et al., 2002). The 
normal FE-1 level is considered to be 200 µg/g. FE-1 levels between 100 to 200 µg/g 
indicate moderate pancreatic insufficiency. FE-1 levels <100 µg/g are thought to indicate 
severe pancreatic insufficiency. The normal adult reference level of 200 µg/g can be 
applied to infants that are older than two weeks, regardless of gestational age, birth 
weight, or nutritional status (Nissler, et al., 2001).  
In the longitudinal study conducted by Campeotto et al. (2002), the FE-1 levels in 
term and preterm infants were collected and compared. The results showed that preterm 
infants had significantly lower FE-1 levels when compared to the term infants. On day 2, 
the results of the FE-1 levels in the term vs. preterm infants were 80 vs. 354 µg/g and on 
day 5 the levels were 164 vs. 600 µg/g. These results suggested pancreatic immaturity in 
preterm infants, especially during the first several weeks of life. The data also showed a 
positive correlation between an increase in FE-1 levels and total nutritional intake. This 
suggests that enteral feedings could an effective strategy for increasing the maturity of 
the GI system at a quicker rate (Nissler et al., 2001). 
In another longitudinal study, conducted by Kori et al. (2001), researchers were 
also able to show that term infants were able to reach normal FE-1 levels at a quicker rate 
than the preterm infants. While it takes an average of 3 days for term infants to reach 
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normal FE-1 levels, it took approximately 2 weeks for the preterm infants to achieve 
these levels.  
While very little research has been conducted in regards to the pancreatic 
secretory and exocrine function of preterm infants, even less has been conducted in 
regards to these functions in preterm infants with BPD. Since pancreatic enzyme activity 
is an essential aspect of the digestive and absorptive process of nutrients and thus, for 
growth within this vulnerable population, further research must be conducted. Because of 
this, the study will examine the pancreatic functionally and exocrine capacity in these 
preterm infants with BPD. It is hypothesized that the preterm infants with BPD will have 
FE-1 levels below the normal accepted rate of 200 µg/g of stool. It is also hypothesized 
that the FE-1 levels in the preterm infants will increase over time.  
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Chapter 3 
Methodology 
A. Research Design 
The study’s design will consist of a repeated measures study in preterm infants with 
BPD. BPD is defined as treatment with mechanical ventilation and/or oxygen therapy for 
at least the first 28 days of life. Thus, in order to be included in the study, the infant must 
be on oxygen at 28 days of life. The infants, with parental consent, will enter the study at 
28 days of life and will be recruited from Grant and Doctors West hospitals, specifically 
from their Neonatal Intensive Care Units (NICU). The pancreatic enzyme activity level 
and growth rates of these preterm infants will be determined. The dependent variable in 
this study is the FE-1 level. Measures of the dependent variable will occur at 4 and 8 
weeks, however, only the data from the first collection point will be reported in this 
study. The requirement for the preterm infants to be included in the 4
th
 week collection 
point is to be at least 28 days post-birth and have been on full enteral feedings for a 
minimum of 72 hours. The rationale for choosing 72 hours is that preterm infants have 
slow and variable intestinal transit time. This will ensure that stool collected will most 
likely represents the full enteral nutrition that the infant received (Leitch & Denne, 2000). 
The 8
th
 week collection point was chosen because by this point the calories should have 
been advanced to the target kcal/kg/day and the infants will have had time to establish a 
pattern of growth.  
B. Sample 
 The sample consisted of 34 preterm infants that were recruited from the NICUs at 
Grant and Doctors West hospitals. The inclusion criteria were as follows. The preterm 
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infants must have had a continuous requirement for positive pressure ventilation and/or 
oxygen therapy at 28 days of life in order to maintain an acceptable pO2 level. The infants 
must have been less than or equal to 29 weeks gestational age, appropriate for gestational 
age, and transitioned to full enteral nutrition. They must have been receiving human milk 
or preterm infant formula for the enteral feedings and the enteral feedings must have been 
provided as bolus feedings. The infants must have received ventilator support with 
oxygen supplementation during the first 72 hours of life in order to manage the 
respiratory distress.  
 The exclusion criteria were as follows. The infant was excluded from the study if 
they suffered from any major congenital malformations, especially respiratory, cardiac, 
or gastrointestinal, or if they had received any major surgery. They were excluded if there 
was an anoxic brain injury at birth or if any postnatal steroids had been used. They were 
also excluded if they were considered to be small for gestational age (birthweight<10
th
 
percentile) or large for gestational age (>90
th
 percentile) because the growth patterns for 
these two groups are different. Infants with necrotizing enterocolitis or any malabsorption 
disorders were also excluded.  If the infant transferred to another hospital besides Grant 
Hospital or Doctors West Hospital during the study, they were also excluded. Finally, the 
infant was excluded if they had received a soy-based or elemental formula during their 
enteral feedings.  
C. Data Collection 
 Stool samples from the preterm infants were collected at approximately 28 days 
of life once full enteral nutrition had been established and again 4 weeks later. For this 
study, only data from the first collection date will be used.  
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D. Procedure  
 Preterm infants were enrolled in the study at 28 days of life if they were able to 
met the required inclusion criteria. At approximately 21 days of life, the preterm infants 
who appeared to be meeting the inclusion criteria were identified as potential participants 
by the nursing staff. The nursing staff then approached the parents of the eligible preterm 
infants and briefly explained the research study. The nurse then requested permission 
from the parents to have a member of the research team contact them and explain the 
study in more detail. If the parents agreed, they were contacted by a member of the 
research team and a full explanation of the study was provided. All questions were 
answered and informed consent from the parents was obtained. The study then began. On 
study days 1 and 26, stool samples were collected over a 72 hour period and pooled 
together. The stool samples were collected by lining the diaper with fat-free paper, which 
has the ability to separate the stool from the urine. These stool samples were then used to 
determine the FE-1 levels of the preterm infants suffering from BPD.  
 Once the stool was collected and pooled for 72 hours, the FE-1 levels were 
determined by using an enzyme-linked immunosorbent assay (ELISA) with a monoclonal 
antibody (ScheBo-Biotech, USA). In preparing the stool sample for the ELISA, each 
sample was diluted in 10 mL of solvent and homogenized using a vibration mixer for 5 
minutes. The suspension was then centrifuged and the supernatant was able to be used for 
analysis. The ELISA has several steps that must be completed in order to determine the 
FE-1 level. First, the stool supernatant was mixed with washing buffer. Then, 50 µl of the 
washing buffer were pipetted into the well of the plate. The plate was then incubated for 
30 minutes at room temperature and the plate was then washed. 50 µl of anti-E1-bio-
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POD-Stretavidin-Complex was added and the plate was incubated for 15 minutes at room 
temperature in the dark. The plate was washed again and a 100 µl of substrate solution 
was added into the wells. The plate was incubated for 15 minutes at room temperature in 
the dark and then 100 µl of Stop solution was added. Finally, the plate was read at OD 
405 and the obtained values were then evaluated with a standard curve. In order to 
enhance the rigor of the study, each stool sample went through this process twice in order 
to ensure accurate readings. 
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Chapter 4 
 
Results 
 
 The sample was comprised of 34 preterm infants with BPD who met the inclusion 
criteria of the larger study.  All the infants were born before 29 weeks gestation and the 
mean gestational age of the group was 27.2 weeks gestation.  The expected normal value 
for FE-1 is greater than 200 µg/g of stool.  The mean FE-1 levels were 287.79 µg/g of 
stool with a standard deviation of ±106.25 µg/g of stool.  The range for the FE-1 values 
was 101.92-520.02 µg/g of stool.  Five infants had levels below 200 µg/g of stool. 
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Chapter 5 
Discussion 
 The purpose of this study was to examine FE-1 levels in extremely preterm 
infants with BPD.  Preterm infants with BPD have been found to excrete higher levels of 
calories (Boehm et al., 1996; Gallagher & Steward, unpublished data).  One logical 
explanation is pancreatic function in relation to pancreatic enzyme activity.  Previous 
researchers have demonstrated that preterm infants with BPD have lower pancreatic 
activity as evidenced by lower levels of trypsin and lipase activity (Boehm et al., 1996).  
The findings from the current study did not support the earlier findings by Boehm and 
colleagues.  The current findings demonstrate that the majority of preterm infants with 
BPD have adequate pancreatic function by the time BPD is diagnosed at 28 days of life.  
There could be several potential explanations for this difference.  Measurement of trypsin 
and lipase occurred by direct aspiration of duodenal secretions via a transpyloric tube.  
This allowed for a more direct assessment of pancreatic function.  Although elastase-1 
remains stable throughout the digestive process (Kori et al., 2003), it may be that 
elastase-1 levels are not as sensitive a measure as direct measure of pancreatic enzymes 
in duodenal secretions.   
 An interesting dilemma is that these data are from a larger study in which these 
infants excreted higher levels of calories.  The reasons for this are unclear but warrant 
further examination since these infants are not maximizing caloric absorption.  Fecal 
analysis of the specific contribution of each of the macronutrients (fat, carbohydrate, and 
protein) to fecal energy loss would shed some light on these energy losses.  Researchers 
have demonstrated that there is a lack of correlation between FE-1 levels and fecal 
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nitrogen levels in stable preterm infants (Corvaglia et al., 2008).  Despite the lack of a 
relationship, fecal nitrogen levels were higher in the preterm infants who were small for 
gestational age at birth.   
 Another important finding from this study that warrants further study is the subset 
of infants who had FE-1 levels below the normal value.  Although not reported in this 
study, levels were measured at two time points, 2-4 weeks later, and were found to have 
increased to normal levels.  It is well established that preterm infants with BPD require 
longer periods of time to transition from parenteral nutrition to full enteral nutrition 
(Khan et al., 2006).  In the current study, the requirement was that the infants had made 
the transition to full enteral nutrition.  It could be that this subset of infants required a 
longer period of time to make the transition.  Rises in FE-1 levels are associated with the 
advancement of enteral nutrition (Campeotto et al., 2002).  It would be interesting to 
follow FE-1 levels during the same period of time that the infants are making the 
transition to full enteral feedings. 
 In conclusion, discovering the reasons for the inadequate growth associated with 
BPD requires continual study.  Based on the findings from this study, preterm infants 
with BPD appear to have normal pancreatic function as evidenced by expected FE-1 
levels.  The higher excretion of calories and the subset of infants who had lower levels at 
28 days of life warrant further examination in this group of preterm infants. 
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